Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 7,441 matching trials from the live ClinicalTrials.gov search.

Filters: Aurora, Colorado Clear all

Conditions: Stroke, Acute
Interventions: Oxygen, placebo; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Aurora, Colorado • Colorado Springs, Colorado

Conditions: Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing, EGFR PACC, EGFR Uncommon Mutations
Interventions: Firmonertinib, EGFR-TKI inhibitor based on investigator's choice; Drug
Lead sponsor: ArriVent BioPharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 21
States / cities: Fullerton, California • Los Angeles, California • Orange, California + 17 more

Conditions: Breast Cancer
Interventions: anastrozole, goserelin acetate; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 57
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 36 more

Conditions: Metastatic Melanoma
Interventions: Lifileucel; Biological
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 23
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 19 more

Conditions: Heart Failure
Interventions: Integrated diagnositic system, Routine in office visits; Other
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 13
States / cities: Anchorage, Alaska • Aurora, Colorado • Tampa, Florida + 10 more

Conditions: COPD Patients
Interventions: Symbicort, Formoterol turbohaler, Placebo for Symbicort pMDI, Placebo for Formoterol Turbohaler; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 95 Years
Enrollment: 2,026 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 224
States / cities: Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 107 more

Conditions: Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
Interventions: Belimumab, Placebo; Biological · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 25
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more

Conditions: Basal Ganglia Germinoma, Diabetes Insipidus, Germinoma, Pineal Region Germinoma, Suprasellar Germinoma, Thalamic Germinoma
Interventions: 3-Dimensional Conformal Proton Radiation Therapy, 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Carboplatin, Etoposide, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Lumbar Puncture, Magnetic Resonance Imaging, Questionnaire Administration, Surgical Procedure; Radiation · Procedure · Drug + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 29 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 97
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 76 more

Conditions: Cerebral Blood Flow, Brain Function
Interventions: acetate, alcohol; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HER2-expressing Cancers
Interventions: ZW25 (Zanidatamab), Paclitaxel, Capecitabine, Vinorelbine, Tucatinib; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 6 more

Conditions: Cystic Fibrosis
Interventions: Ataluren; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 6 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 7
States / cities: Birmingham, Alabama • Long Beach, California • Aurora, Colorado + 4 more

Conditions: TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
Interventions: Not listed
Lead sponsor: Personalis Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 14
States / cities: Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 11 more

Conditions: Aortic Stenosis
Interventions: Medtronic TAV, Edwards TAV; Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: 18 Years to 105 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more

Conditions: Contraception
Interventions: ESS505 (BAY1454033); Device
Lead sponsor: Bayer; Industry
Eligibility: 21 Years to 44 Years · Female only
Enrollment: 660 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2024
U.S. locations: 17
States / cities: Aurora, Colorado • Denver, Colorado • Wellington, Florida + 14 more

Conditions: Arrhythmogenic Right Ventricular Cardiomyopathy
Interventions: TN-401; Genetic
Lead sponsor: Tenaya Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 7
States / cities: San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 4 more

Conditions: Breast Cancer
Interventions: ramucirumab (IMC-1121B), docetaxel, Placebo; Biological · Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 65
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 52 more

Conditions: Lymphoma
Interventions: filgrastim, rituximab, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 104
States / cities: Palo Alto, California • Fort Collins, Colorado • Jacksonville, Florida + 69 more

Conditions: AML, MDS
Interventions: SOC + TSC-101, Control, SOC + TSC-100; Drug · Other
Lead sponsor: TScan Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 21
States / cities: Duarte, California • Aurora, Colorado • Denver, Colorado + 16 more

Conditions: Homocystinuria Due to CBS Deficiency
Interventions: Not listed
Lead sponsor: Travere Therapeutics, Inc.; Industry
Eligibility: 1 Year to 65 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 7
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more

Conditions: Barrett Esophagus, Esophageal Cancer
Interventions: EnteroTracker; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 45 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Adult Meningioma
Interventions: hydroxyurea; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2011
U.S. locations: 133
States / cities: Fairbanks, Alaska • Phoenix, Arizona • Little Rock, Arkansas + 97 more

Conditions: Age Problem, Morality, Arrhythmias, Cardiac
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 65 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Post-operative Pain
Interventions: Bupivicaine, placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 20 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Acanthamoeba Keratitis
Interventions: Polyhexamethylene biguanide (PHMB), Topical corticosteroid, Topical placebo; Drug · Other
Lead sponsor: Jeremy Keenan, MD, MPH; Other
Eligibility: 8 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 18
States / cities: Irvine, California • Los Angeles, California • San Francisco, California + 13 more

Search by objective public record fields.

The Role of Hyperoxia in Acute Ischemic Stroke

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

Feasibility Study of an Integrated Diagnostic System to Manage Heart Failure

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

Effects of Acetate and Alcohol on Brain Function

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Study of Ataluren (PTC124) in Cystic Fibrosis

CtDNA Based MRD Testing for NAC Monitoring in TNBC

REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women

Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA)

Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)

Study to Evaluate EnteroTracker® as a Sampling Method to Screen for Barrett's Esophagus/Esophageal Cancer

S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma

Use of Device Data to Predict Frailty in Individuals

Effectiveness of Continuous Femoral Nerve Block Versus Single Shot Femoral Nerve Block for Pain Control

Parasitic Ulcer Treatment Trial